Andrew S. Bomback, MD, MPH, recalls a patient from over a decade ago, who traveled to New York for a second opinion on his IgA nephropathy diagnosis. The patient had researched his condition and accurately anticipated that prednisone would be the recommended treatment, expressing frustration over the lack of alternatives.
At the time, Dr Bomback shared that frustration, as prednisone was the only available option despite the disease’s prevalence. Now, he reflects on the remarkable progress in the field, with new therapies such as complement inhibitors, enteric-targeted steroids, and endothelin receptor antagonists, offering patients a broader range of effective treatments beyond traditional steroids.
